Future therapeutic directions for Smac-Mimetics

Author(s): Morrish, E; Brumatti, G; Silke, J;
Details: Publication Year 2020-02-11,Volume 9,Issue #2,Page 406
Journal Title: Cells
Publication Type: Journal Article
Abstract: It is well accepted that the ability of cancer cells to circumvent the cell death program that untransformed cells are subject to helps promote tumor growth. Strategies designed to reinstate the cell death program in cancer cells have therefore been investigated for decades. Overexpression of members of the Inhibitor of APoptosis (IAP) protein family is one possible mechanism hindering the death of cancer cells. To promote cell death, drugs that mimic natural IAP antagonists, such as second mitochondria-derived activator of caspases (Smac/DIABLO) were developed. Smac-Mimetics (SMs) have entered clinical trials for hematological and solid cancers, unfortunately with variable and limited results so far. This review explores the use of SMs for the treatment of cancer, their potential to synergize with up-coming treatments and, finally, discusses the challenges and optimism facing this strategy.
Publisher: MDPI
Research Division(s): Inflammation
PubMed ID: 32053868
Publisher's Version: https://doi.org/10.3390/cells9020406
Open Access at Publisher's Site: https://doi.org/10.3390/cells9020406
NHMRC Grants: NHMRC/1025594, NHMRC/1046010, NHMRC/1081376, NHMRC/1107149,
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2020-05-04 11:46:52

Last Modified: 2020-05-04 02:06:49